Satellos Bioscience Inc. (MSCL) - Total Liabilities
Based on the latest financial reports, Satellos Bioscience Inc. (MSCL) has total liabilities worth CA$4.10 Million CAD (≈ $2.96 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Satellos Bioscience Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Satellos Bioscience Inc. - Total Liabilities Trend (2019–2025)
This chart illustrates how Satellos Bioscience Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Satellos Bioscience Inc. Competitors by Total Liabilities
The table below lists competitors of Satellos Bioscience Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
Germany | €20.17 Billion |
|
Red Hill Minerals Ltd
AU:RHI
|
Australia | AU$10.26 Million |
|
Yatsen Holding
NYSE:YSG
|
USA | $809.74 Million |
|
Peninsula Group Ltd
TA:PEN
|
Israel | ILA1.23 Billion |
|
COG Financial Services Ltd
AU:COG
|
Australia | AU$536.47 Million |
|
Meridian Bank
NASDAQ:MRBK
|
USA | $2.38 Billion |
|
CSG Holding Co Ltd
SHE:200012
|
China | HK$18.01 Billion |
|
Decora SA
WAR:DCR
|
Poland | zł167.90 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Satellos Bioscience Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Satellos Bioscience Inc. (MSCL) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.39 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Satellos Bioscience Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Satellos Bioscience Inc. (2019–2025)
The table below shows the annual total liabilities of Satellos Bioscience Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$4.10 Million ≈ $2.96 Million |
-20.51% |
| 2024-12-31 | CA$5.16 Million ≈ $3.73 Million |
+42.25% |
| 2023-12-31 | CA$3.62 Million ≈ $2.62 Million |
+28.06% |
| 2022-12-31 | CA$2.83 Million ≈ $2.05 Million |
+34.51% |
| 2021-12-31 | CA$2.10 Million ≈ $1.52 Million |
+60.21% |
| 2020-12-31 | CA$1.31 Million ≈ $950.00K |
+97.54% |
| 2019-12-31 | CA$664.81K ≈ $480.91K |
-- |
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more